Sugi Predict

Sugi Predict / Targets / GPR183

GPR183

G-protein coupled receptor 183 · P32249 · GPR183 on Sugi Atlas →

53,228 patent compounds predicted against GPR183, 36,876 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL118378 SCHEMBL118378 0.43 9/20
SCHEMBL281941 SCHEMBL281941 1.00 6/20
SCHEMBL281942 SCHEMBL281942 1.00 6/20
SCHEMBL281943 SCHEMBL281943 1.00 6/20
SCHEMBL289219 SCHEMBL289219 1.00 6/20
SCHEMBL363463 SCHEMBL363463 0.60 6/20
SCHEMBL301939 SCHEMBL301939 0.51 6/20
SCHEMBL296570 SCHEMBL296570 0.40 5/20
SCHEMBL296571 SCHEMBL296571 0.40 5/20
SCHEMBL365871 SCHEMBL365871 0.39 5/20
7-Oxocholesterol 7-Oxocholesterol (SCHEMBL231535) 0.67 4/20
7-Oxocholesterol 7-Oxocholesterol (SCHEMBL231536) 0.67 4/20
SCHEMBL255026 SCHEMBL255026 0.51 4/20
SCHEMBL28379 SCHEMBL28379 0.51 3/20
SCHEMBL377743 SCHEMBL377743 0.61 2/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL211137) 0.57 2/20
SCHEMBL90762 SCHEMBL90762 0.52 2/20
SCHEMBL248175 SCHEMBL248175 0.50 2/20
SCHEMBL56987 SCHEMBL56987 0.47 2/20
SCHEMBL105066 SCHEMBL105066 0.47 2/20

Clinical trials — most relevant to GPR183 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell. PHASE4UNKNOWN
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration PHASE2WITHDRAWN
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin PHASE2UNKNOWN
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma PHASE2UNKNOWN
Carbidopa-levodopa in Neovascular AMD PHASE2COMPLETED
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment PHASE1/PHASE2RECRUITING
Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS) PHASE2COMPLETED
Sweet Taste Receptors and the Secretion of Glucagon-like Peptide-1 and Peptide YY PHASE1COMPLETED
Role of the Gut Sweet Taste Receptor in the Secretion of Glucagon-like Peptide-1 and Peptide YY PHASE1COMPLETED
The Role of Endocannabinoids in Insulin Production and Action PHASE1COMPLETED
Oat Bran and Plasma Lipid and Fecal Bacteria in Coronary Artery Disease Patients nanCOMPLETED
The Application of 68Ga-Pentixafor Alongside 68Ga-FAPI-04 PET/MR for Assessing Primary Aldosteronism. nanNOT_YET_RECRUITING
FFAR Agonist on Incretins, Insulin, Lipids and Inflammation nanCOMPLETED
Dose-response Effect of Pine Nut Oil as a Dual FFA1 and FFA4 Agonist on Glucose Tolerance in Healthy Humans. nanCOMPLETED
Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment nanNOT_YET_RECRUITING
Neutrophil FFA2/GPR43 Receptor Expression in Patients With the Diagnosis of Sepsis nanWITHDRAWN
Gastroparesis Registry 3 nanCOMPLETED
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures nanCOMPLETED
Effects of Probiotics on Gut Microbiota, Endocannabinoid and Immune Activation and Symptoms of Fatigue in Dancers nanCOMPLETED
Effect of Dietary Oils as G-protein-coupled Receptor Agonists on Glucose Tolerance nanUNKNOWN
Selective Activation of the Adrenomedullin Receptors in Migraine nanNOT_YET_RECRUITING
Investigating Optimal Propionate Delivery to the Colon Using Stable Isotope Labeling nanCOMPLETED
RCT to Describe the Effects of Colon Delivered Acetate, Propionate and Butyrate on Satiety and Glucose Homeostasis nanCOMPLETED
Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness nanUNKNOWN
Forced Oscillometry in Infants With Bronchopulmonary Dysplasia nanRECRUITING
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity nanNOT_YET_RECRUITING
The Anatomical Location, Cellular Origin and Molecular Basis of Gut-derived Glucagon Secretion nanCOMPLETED
Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists. nanRECRUITING
Circular RNA and Chemerin in Breast Cancer Patient nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a GPR183 binder may also engage these)

ProteinNameSimilarity
D4A7K7 — 1.000 D4A7K7 →
Q3U6B2 — 1.000 Q3U6B2 →
A5PLE7 — 1.000 A5PLE7 →
Q3U507 — 0.997 Q3U507 →
Q1RMI1 — 0.997 Q1RMI1 →
Q924T8 — 0.996 Q924T8 →
Q95N02 — 0.994 Q95N02 →
B0UXR0 — 0.994 B0UXR0 →
Q61038 — 0.994 Q61038 →
B5X337 — 0.992 B5X337 →
Q99JA4 — 0.990 Q99JA4 →
GPR65 G-protein coupled receptor 65 0.990 landscape →
Q9GK76 — 0.990 Q9GK76 →
Q9Z0Z6 — 0.989 Q9Z0Z6 →
Q9XSD4 — 0.989 Q9XSD4 →
Q9TTY5 — 0.989 Q9TTY5 →
Q62035 — 0.989 Q62035 →
Q2NNR5 — 0.988 Q2NNR5 →
P79785 — 0.988 P79785 →
GPR174 Probable G-protein coupled receptor 174 0.988 landscape →
PTAFR Platelet-activating factor receptor 0.988 landscape →
P35374 — 0.987 P35374 →
Q95N03 — 0.987 Q95N03 →
P2RY10 Putative P2Y purinoceptor 10 0.987 landscape →
P46002 — 0.986 P46002 →
Q3SAG9 — 0.985 Q3SAG9 →
GPR34 Probable G-protein coupled receptor 34 0.985 landscape →
P21556 — 0.985 P21556 →
Q0VDU3 — 0.985 Q0VDU3 →
CYSLTR2 Cysteinyl leukotriene receptor 2 0.984 landscape →